These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 39257124)

  • 21. A chronic myeloid leukemia case with a variant translocation t(11;22) (q23;q11.2): masked Philadelphia or simple variant translocation?
    Acar K; Uz B
    Pan Afr Med J; 2018; 30():161. PubMed ID: 30455790
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Leukemia cell lines: in vitro models for the study of Philadelphia chromosome-positive leukemia.
    Drexler HG; MacLeod RA; Uphoff CC
    Leuk Res; 1999 Mar; 23(3):207-15. PubMed ID: 10071072
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cytogenetical and hematological analysis of chronic myelogenous leukemia patients with a novel case 52XX, t (1;9;22) (q23.3; q34; q11.2), +6, +8, i(9) (q10;q10), +18,+19,+21+der22 t(9;22)(q34;q11).
    Asif M; Hussain A; Ali I; Baloch Z; Rasool M; Achakzai NM
    Medicine (Baltimore); 2022 Nov; 101(45):e31670. PubMed ID: 36397339
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Chronic myelogenous leukemia with acquired t(11;14)(q13;q32) CCND1-IGH: A case report and literature review.
    Manda-Mapalo MT; Khalili P; Quintana D; Rabinowitz I; Zhang QY
    Cancer Genet; 2016 Oct; 209(10):481-485. PubMed ID: 27810077
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Does presence of complex translocations involving BCR::ABL1 in chronic myeloid leukemia affect the response rate to tyrosine kinase inhibitors? A systematic review of the literature.
    Sharma D; Wilson C; Kumar S; Ghose S; Sahoo R; Sharawat SK
    Ann Diagn Pathol; 2024 Aug; 71():152303. PubMed ID: 38636337
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of tyrosine kinase inhibitors for controlling Ph+ clone and additional clonal abnormalities in a chronic myeloid leukemia.
    Ganguly BB; Mandal S; Banerjee D; Kadam NN
    J Cancer Res Ther; 2022; 18(3):760-764. PubMed ID: 35900551
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Isodicentric Philadelphia Chromosome: A Rare Chromosomal Aberration in Imatinib-Resistant Chronic Myelogenous Leukemia Patients - Case Report with Review of the Literature.
    Ramachandran KC; Narayanan G; Nair SG; Thambi SM; Kamala LH; Gopinath P; Sreedharan H
    Cytogenet Genome Res; 2016; 150(3-4):273-280. PubMed ID: 28253493
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Research advance on molecular genetics of CML blast crisis].
    Zhu HQ; Zhang S; Liu XL
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2008 Feb; 16(1):217-21. PubMed ID: 18315935
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clonal Evolution and Blast Crisis Correlate with Enhanced Proteolytic Activity of Separase in BCR-ABL b3a2 Fusion Type CML under Imatinib Therapy.
    Haaß W; Kleiner H; Weiß C; Haferlach C; Schlegelberger B; Müller MC; Hehlmann R; Hofmann WK; Fabarius A; Seifarth W; ;
    PLoS One; 2015; 10(6):e0129648. PubMed ID: 26087013
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Chronic myeloid leukemia: 2020 update on diagnosis, therapy and monitoring.
    Jabbour E; Kantarjian H
    Am J Hematol; 2020 Jun; 95(6):691-709. PubMed ID: 32239758
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Therapeutic effects of tyrosine kinase inhibitors and subtypes of BCR-ABL1 transcripts in Japanese chronic myeloid leukemia patients with three-way chromosomal translocations.
    Inokuchi K; Nakayama K; Tauchi T; Takaku T; Yokose N; Yamaguchi H; Kumagai T; Komatsu N; Ohyashiki K
    Leuk Res; 2018 Feb; 65():74-79. PubMed ID: 29310021
    [TBL] [Abstract][Full Text] [Related]  

  • 32. ApoptomiRs expression modulated by BCR-ABL is linked to CML progression and imatinib resistance.
    Ferreira AF; Moura LG; Tojal I; Ambrósio L; Pinto-Simões B; Hamerschlak N; Calin GA; Ivan C; Covas DT; Kashima S; Castro FA
    Blood Cells Mol Dis; 2014; 53(1-2):47-55. PubMed ID: 24629639
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia.
    Steinberg M
    Clin Ther; 2007 Nov; 29(11):2289-308. PubMed ID: 18158072
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Clinical significance of clonal evolution in chronic myeloid leukemia].
    Ochi Y
    Rinsho Ketsueki; 2023; 64(5):369-375. PubMed ID: 37271527
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The use of Imatinib resistance mutation analysis to direct therapy in Philadelphia chromosome/BCR-ABL1 positive chronic myeloid leukaemia patients failing Imatinib treatment, in Patan Hospital, Nepal.
    Kayastha GK; Ranjitkar N; Gurung R; Kc RK; Karki S; Shrestha R; Rajbhandari P; Thapa RK; Poudyal B; Acharya P; Roberts DJ; Hayes B; Zimmerman M; Basnyat B
    Br J Haematol; 2017 Jun; 177(6):1000-1007. PubMed ID: 28467002
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Impact of additional genetic abnormalities at diagnosis of chronic myeloid leukemia for first-line imatinib-treated patients receiving proactive treatment intervention.
    Shanmuganathan N; Wadham C; Shahrin N; Feng J; Thomson D; Wang P; Saunders V; Kok CH; King RM; Kenyon RR; Lin M; Pagani IS; Ross DM; Yong ASM; Grigg AP; Mills AK; Schwarer AP; Braley J; Altamura H; Yeung DT; Scott HS; Schreiber AW; Hughes TP; Branford S
    Haematologica; 2023 Sep; 108(9):2380-2395. PubMed ID: 36951160
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Detection of BCR-ABL1 kinase domain mutations causing imatinib resistance in chronic myelogenous leukemia.
    Moore FR; Yang F; Press RD
    Methods Mol Biol; 2013; 999():25-39. PubMed ID: 23666688
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Initial molecular response at 3 months may predict both response and event-free survival at 24 months in imatinib-resistant or -intolerant patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase treated with nilotinib.
    Branford S; Kim DW; Soverini S; Haque A; Shou Y; Woodman RC; Kantarjian HM; Martinelli G; Radich JP; Saglio G; Hochhaus A; Hughes TP; Müller MC
    J Clin Oncol; 2012 Dec; 30(35):4323-9. PubMed ID: 23109697
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Predictive and Prognostic Implications of Variant Philadelphia Translocations in CML: Experience From a Tertiary Oncology Center in Southern India.
    Kanakasetty GB; Kuntejowdahalli L; Thanky AH; Dasappa L; Jacob LA; Mallekavu SB; Kumari P
    Clin Lymphoma Myeloma Leuk; 2017 Jan; 17(1):52-59. PubMed ID: 27743980
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Chronic myeloid leukemia with two rare fusion gene transcripts of atypical BCR::ABL: A case report and literature review.
    Li Y; Zhang Y; Meng X; Chen S; Wang T; Zhang L; Ma X
    Medicine (Baltimore); 2024 Jan; 103(3):e36728. PubMed ID: 38241589
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.